DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/89c566/spain_pharmaceutic) has announced the addition of the "Spain Pharmaceuticals and Healthcare Report Q4 2011" report to their offering.
Business Monitor International's Spain Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Spain's pharmaceuticals and healthcare industry.
The Spanish government's decision to implement further austerity measures is seen as a necessary and prudent course of action. The country still has the third highest budget deficit in the eurozone and continues to receive negative attention from bond markets. However, its decision to further target the pharmaceuticals and healthcare sector will not sit well with drug companies, as the overall austerity measures have had a crimping effect on overall economic growth in Spain. Cost-containment within the healthcare sector will significantly affect revenue-earning opportunities for drugmakers.
Key Trends & Developments:
On July 21 2011, the country's Ministry of Health and the inter-territorial cabinet of ministers approved new austerity measures aiming to cut spending on drugs by EUR2.4bn (US$3.4bn).
In August 2011, it was revealed that jobs in the Spanish pharmaceutical sector are under threat as the government is delaying payments for medicines. This led to the shutdown of operations in approximately 85% of 1,300 pharmacies in the Castilla-La Mancha region for a day. The pharmacies were protesting against the government's lack of payment of debts totalling EUR130mn (US$184mn), according to Dolores Espinosa, president of a regional pharmacy industry group.
Headline Expenditure Projections:
Pharmaceuticals: EUR16.08bn (US$21.33bn) in 2010 to EUR15.57bn (US$22.26bn) in 2011; -3.2% in local currency terms and +4.4% in US dollar terms.
Healthcare: EUR103.15bn (US$136.83bn) in 2010 to EUR105.13bn (US$150.33bn) in 2011; +1.9% in local currency terms and +9.9% in US dollar terms.
Medical Devices EUR4.10bn (US$5.44bn) in 2010 to EUR4.20bn (US$6.01bn) in 2011; +2.5% in local currency terms and +10.5% in US dollar terms.
Key Topics Covered by "Spain Pharmaceuticals and Healthcare Report Q4 2011":
- SWOT Analyses
- Pharmaceutical Business Environment Ratings
- Spain - Market Summary
- Regulatory Regime
- Industry Developments
- Industry Forecast Scenario
- Competitive Landscape
- Company Profiles
- Country Snapshot: Spain Demographic Data
For more information, including full table of contents and list of companies mentioned, please visit http://www.researchandmarkets.com/research/89c566/spain_pharmaceutic